Skip to Content

Oppenheimer predicts Icosavax, Inc. (NASDAQ:ICVX) will earn ($2.37) per share in fiscal year 2022.

Oppenheimer predicts Icosavax, Inc. (NASDAQ:ICVX) will earn ($2.37) per share in fiscal year 2022.

NASDAQ: ICVX Icosavax Inc The projections regarding Icosavax’s profitability for the fiscal year 2022 that were made by analysts working for Oppenheimer were made public in the form of a research note on Tuesday, January 3. H. Singh, an analyst at Oppenheimer, has predicted that the company will report a loss of $2.37 per share in 2017. These projections were made in 2017. The investment bank Oppenheimer currently assigns the company an “Outperform” rating, and their price objective for the company is established at $27.00. Icosavax’s earnings are expected to come in at $2.27 per share for the full year, according to the consensus figure. Icosavax is expected to earn $0.63 per share in the fourth quarter of 2022, $2.19 per share in the first fiscal year of 2023, $2.26 in the second fiscal year of 2024, $2.21 in the first fiscal year of 2025, and $1.07 in the first fiscal year of 2026, according to the projections made by Oppenheimer. These forecasts of the company’s profits about the stock of the company.
When trading on ICVX began on Friday, the stock was trading for $7.49. The company’s market capitalization is currently sitting at $298.70 million, its price-to-earnings ratio is currently sitting at -3.44, and its beta value currently sits at 0.24. Icosavax hit an all-time high of $19.56 in the last year, while it hit an all-time low of $2.28 in the same period. The company’s simple moving average for the past fifty days is $5.08, and the simple moving average for the past 200 days is $5.54.
Icosavax (NASDAQ: ICVX) announced the outcomes of its most recent quarterly earnings report on Monday, November 14. The actual earnings per share for the quarter were $0.55, which is $0.02 higher than the consensus estimate of earnings per share for the quarter, which was $0.57. The earnings for the quarter were reported in Canadian dollars.
As a result of recent occurrences, institutional investors and hedge funds have modified their positions within the industry. Icosavax was the beneficiary of a 6.1% increase in the holdings made by the Swiss National Bank during the first three months of 2018. The Swiss National Bank now has 27,700 shares of the company’s stock, which have a combined value of $195,000 after acquiring an additional 1,600 shares during the most recent fiscal quarter. These 27,700 shares have a total value of $195,000. During the second quarter, Ensign Peak Advisors Inc. significantly increased the percentage of Icosavax stock owned by a factor of 329.9%. Ensign Peak Advisors Inc. has increased the value of its holdings by $33,000 by purchasing an additional 4,420 shares of the company’s stock over the past two months. This brings the total value of its holdings to $33,000. The holdings of Icosavax, owned by American International Group Inc., increased by 68.9% during the first three months of the current year. American International Group Inc. is now the owner of 12,005 shares, valued at $85,000, thanks to purchasing an additional 4,896 shares during the most recent time frame. The California State Teachers Retirement System bought an additional 30.4% more Icosavax stock during the first three months of 2018, bringing the total amount of the company’s stock to 100%. After making an additional purchase of 5,272 shares during the period, the California State Teachers Retirement System now has 22,596 shares of the company’s stock, which are currently valued at $159,000. This is because the California State Teachers Retirement System owns 22,596 shares of the company’s stock. And finally, throughout the third quarter, the Bank of New York Mellon Corporation increased the proportion of Icosavax stock owned by an additional 12.0%. The Bank of New York Mellon Corp. now has 64,907 shares of the company’s stock, currently valued at $205,000, after purchasing an additional 6,972 shares during the period in question. These shares were purchased during the period in question. The majority of the shares in the company are owned by institutional investors and hedge funds, which account for 80.54% of the total number of shares.
Additionally, on December 21, 66,764 shares of the company’s stock were sold by Adam K. Simpson, the Chief Executive Officer of the business. Because each share was sold for an average price of $8.96, the total amount of money transacted during the sale was 598,205.44 dollars. After the sale, the CEO will have a direct ownership stake in the company equal to 225,105 shares, which will have a value of approximately $2,016,940.80 at the time of this writing. The Securities and Exchange Commission was given legal documentation about the transaction, which can be viewed entirely by following the link provided in the previous sentence. The documentation was provided to the SEC. In addition, on December 15, Douglas Holtzman, an executive who worked for the company, sold 19,648 shares of the company’s stock. Another piece of recent news is as follows. The price of one share of stock, which, when sold, brought in a total of $218,878.72, came to an average of $11.14 per share. The completion of the transaction has resulted in the corporate insider owning 2,792 shares of the company, which have a value of $31,102.88 each. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail. In addition, on December 21, 66,764 shares of the company’s stock were sold by Adam K. Simpson, who serves as the company’s Chief Executive Officer. The total value of the traded stock was 598,205.44 dollars, corresponding to an average price of $8.96 per share paid for the transaction. As a direct result of the transaction, the company’s Chief Executive Officer (CEO) now owns 225,105 company shares, each of which is currently valued at approximately $2,016,940.80. Disclosures that are related to the sale might be found in this section of the website. At this time, company insiders own 39.09% of the stock in the company.
Icosavax, Inc. is a biopharmaceutical company in the business of producing vaccinations meant to protect against infectious diseases. The company uses the virus-like particle (VLP) platform technology it developed to combat potentially fatal respiratory conditions. The company developed this technology. In the ongoing clinical trial known as Phase 1/1b, the vaccine candidate known as IVX-121 is being tested for its ability to protect against RSV. IVX-A12 is a candidate for a monovalent antigen against the respiratory syncytial virus (RSV), and it also has a bivalent target indication against respiratory syncytial virus and human metapneumovirus (hMPV). IVX-241 is a potential candidate for use in a vaccine that targets hMPV. IVX-411 is a unique receptor-binding protein in its own right. Other products are currently in development for it.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *